Cargando…

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations

Detalles Bibliográficos
Autores principales:	Gaibani, Paolo, Tonetti, Tommaso, Bartoletti, Michele, Re, Maria Carla, Viale, PierLuigi, Ranieri, V. Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833089/ https://www.ncbi.nlm.nih.gov/pubmed/33385588 http://dx.doi.org/10.1016/j.jgar.2020.12.011

Ejemplares similares

The lower respiratory tract microbiome of critically ill patients with COVID-19
por: Gaibani, Paolo, et al.
Publicado: (2021)

The Gut Microbiota of Critically Ill Patients With COVID-19
por: Gaibani, Paolo, et al.
Publicado: (2021)

Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.
por: Viciani, Elisa, et al.
Publicado: (2022)

Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients
por: Gatti, Milo, et al.
Publicado: (2022)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
por: Gaibani, Paolo, et al.
Publicado: (2022)

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis
por: Gatti, Milo, et al.
Publicado: (2023)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
por: Gatti, Milo, et al.
Publicado: (2023)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2021)

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
por: Gaibani, Paolo, et al.
Publicado: (2021)

Klebsiella pneumoniae Bloodstream Infection: Epidemiology and Impact of Inappropriate Empirical Therapy
por: Girometti, Nicolò, et al.
Publicado: (2014)

Hospital-Acquired Infections in Critically Ill Patients With COVID-19
por: Grasselli, Giacomo, et al.
Publicado: (2021)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases
por: Gatti, Milo, et al.
Publicado: (2022)

Opportunistic infections in end stage liver disease
por: Bartoletti, Michele, et al.
Publicado: (2018)

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study
por: Bartoletti, Michele, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
por: Gatti, Milo, et al.
Publicado: (2022)

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
por: Troisi, Carla, et al.
Publicado: (2023)

Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study
por: Pascale, Renato, et al.
Publicado: (2021)

Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae
por: Viale, Pierluigi, et al.
Publicado: (2015)

Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2021)

Antiviral agents in the critically ill child
por: Munoz, Flor M.
Publicado: (2000)

Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)
por: Bartoletti, Michele, et al.
Publicado: (2020)

Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545–1553
por: Bartoletti, Michele, et al.
Publicado: (2023)

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
por: Pascale, Renato, et al.
Publicado: (2021)

Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy
por: Tonetti, Tommaso, et al.
Publicado: (2020)

Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence
por: Campione, Elena, et al.
Publicado: (2021)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
por: Paolisso, Pasquale, et al.
Publicado: (2020)

Antiviral prophylaxis inhibits cytomegalovirus reactivation in critical illness
por: Cowley, NJ, et al.
Publicado: (2015)

Antiviral activities of interferons
por: Stewart, William E., et al.
Publicado: (1979)

Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
por: Viale, Pierluigi, et al.
Publicado: (2023)

Meningitis Caused by Toscana Virus Is Associated with Strong Antiviral Response in the CNS and Altered Frequency of Blood Antigen-Presenting Cells
por: Varani, Stefania, et al.
Publicado: (2015)

Effects of iron deficiency on transfusion requirements in critically ill patients: a preliminary observational study
por: Aydogan, M, et al.
Publicado: (2015)

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
por: Arabi, Yaseen M, et al.
Publicado: (2020)

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
por: Aricò, Eleonora, et al.
Publicado: (2021)

Interferon-inducible antiviral effectors
por: Sadler, Anthony J., et al.
Publicado: (2008)

Antiviral defense: interferons and beyond
por: Stetson, Daniel B., et al.
Publicado: (2006)

Avian Interferons and Their Antiviral Effectors
por: Santhakumar, Diwakar, et al.
Publicado: (2017)

Transpulmonary Pressure to Guide Mechanical Ventilation: Art or Science?
por: Ranieri, V. Marco, et al.
Publicado: (2021)

Effects of acute critical illnesses on the performance of interferon-gamma release assay
por: Huang, Chun-Ta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eue1iv12a5gefa799l5v7irvja